Submandibular Gland Management in Level II Neck Dissection for Oral Cavity SCC
In elective (N0) neck dissection for oral cavity squamous cell carcinoma, the submandibular gland can be safely preserved, whereas in therapeutic (N+) neck dissection, the gland should be removed as part of comprehensive level I-V dissection.
Algorithmic Approach
For Elective (cN0) Neck Dissection:
- Preserve the submandibular gland in early-stage disease (T1-T2, N0)
- Perform selective neck dissection of levels I-III at minimum 1
- Level IB lymph nodes should be removed, but the gland itself can be spared
Rationale: The submandibular gland itself is rarely involved in early-stage oral cavity cancer. Recent meta-analyses show SMG involvement occurs in only 1.55% of cases overall 2, with the vast majority (90.34%) occurring in T3-T4 disease and 93.07% in N+ disease 2. In early-stage N0 disease, SMG preservation does not increase locoregional recurrence (RR 1.05, p=0.81), affect disease-specific survival (RR 0.86, p=0.69), or alter overall survival (RR 0.80, p=0.57) 3.
For Therapeutic (cN+) Neck Dissection:
- Remove the submandibular gland as part of comprehensive dissection
- Extend dissection to levels I-V for clinically positive nodes 1
- The gland is at higher risk due to direct extension or extranodal extension from level IB nodes
Rationale: When regional metastases are present, levels I-V show involvement rates of 52%, 77%, 73%, 53%, and 40% respectively 4. The mechanism of SMG involvement in advanced disease is primarily through direct tumor extension (0.83% of cases) or extranodal extension from adjacent level IB nodes (0.28%) 2. Intraglandular lymph node metastases are exceedingly rare 5.
Key Clinical Considerations
Specific Indications for SMG Preservation (All Must Be Present):
- Clinical stage T1-T2
- Clinical N0 neck status
- No tumor proximity to level IB requiring wide margins
- No evidence of level IB nodal involvement on imaging
Contraindications to SMG Preservation:
- T3-T4 tumors (90% of SMG involvement occurs here) 2
- Any clinical nodal disease (N1-N3)
- Tumors with direct extension toward level IB
- Intraoperative findings of level IB extranodal extension
- Tumors of the floor of mouth or anterior tongue approaching/crossing midline requiring contralateral submandibular dissection 1
Quality of Life Impact
The submandibular gland produces 70-90% of unstimulated saliva 6. Its removal increases xerostomia incidence from 7% to 21% 6. However, preservation in appropriate candidates shows zero incidence of xerostomia without compromising oncologic safety 7. This functional benefit is significant for long-term quality of life, particularly in early-stage disease where cure rates are high.
Common Pitfalls to Avoid
- Do not preserve the gland based solely on imaging - Intraoperative assessment of level IB nodes is critical; if extranodal extension is found, remove the gland
- Do not attempt preservation in floor of mouth primaries - These have higher risk of direct extension to level IB
- Do not confuse level IB node removal with gland removal - Level IB lymph nodes must always be removed; the gland itself can be preserved in selected cases
- Avoid preservation if surgical margins would be compromised - Oncologic clearance always takes priority over gland preservation
The evidence strongly supports a risk-stratified approach: preservation is oncologically safe in carefully selected early-stage N0 patients 3, 8, 2, while therapeutic dissections require comprehensive removal including the submandibular gland to address the higher risk of involvement through direct extension or nodal extracapsular spread.